BioPharm America is just around the corner! The 8th Annual International Partnering Conference is set to take place September 15-17 at the Boston Marriott Copley Place.
BioPharm America™ is where biotech industry partnerships get started. Meet face-to-face with biotech and pharma executives from around the world to identify and enter strategic relationships. Equipped with partneringONE®, the world’s leading web-based partnering system for the life science industry, BioPharm America is the only event in North America based on the same reputable formula as EBD Group’s acclaimed European events BIO-Europe® and BIO-Europe Spring®.
Benefits of partneringONE:
- Conduct more meetings at one conference than in the rest of the year
- Contact existing and potential partners prior to the conference
- Manage all your conference activities in one place
- Your meetings will be prescheduled to maximize your time on site.
Biotech Startup Day is a powerful opportunity to present your company to Boston’s leading financiers, pharma dealmakers and biotech business KOLs. This special program is specifically designed for early stage projects and young companies to get on the radar of the global life science community and to make the connections that matter. Learn more & register
This year’s conference has an impressive lineup of speakers, including a special executive discussion with rare disease leaders:
***MassBio Members receive an additional $200 off! Just type “MassBio” in the comments field!***
Applied Photophysics Inc. (APL) has firmly established itself as a global developer and manufacturer of high quality, high performance, modern CD spectrometers for the study of structural, thermodynamic and kinetic properties of a wide range of samples with particular focus on proteins and other bio-macromolecules. Website
Checkmate Pharma is developing a new approach for cancer immunotherapy, activating the immune system in a specific manner to recognize and kill tumor cells throughout the body, without harming normal tissues. Website
The German Accelerator supports German tech startups to enter the U.S. market. The German Accelerator provides startups with hands-on mentoring at its locations in Silicon Valley, San Francisco, New York City, and from January 2016 onwards also in Boston. The three months program is open to a broad range of startups from ICT related sectors. The new Accelerator in Boston will have a particular focus on Life Science. Ideal participants generate domestic revenue, enjoy customer traction and have the potential for category leadership in a large, global market. Website
Imagen is a biopharmaceutical company engaged in the development of precision therapeutics for a broad range of human diseases. Imagen’s therapeutic and discovery technologies capture the principal advantages of T cell-based immunotherapies while addressing many of the limitations and toxicities seen in the current immunotherapeutics landscape. Website
New Paradigm Biosciences
New Paradigm Biosciences is a biotech company dedicated to developing therapies using humanized mouse models and other cutting edge technologies. The Company has exclusive licenses to technologies developed at MIT, University of North Carolina and Singapore-MIT Alliance for Research and Technology. It has operations in both US and Asia. Website
Selvita Inc. was incorporated in February 2015 and is located in Cambridge MA. It is a wholly owned subsidiary of Selvita S.A. Selvita S.A. is well-established, publicly-held company based in Krakow, Poland, which delivers services as a Contract Research Organization and is actively engaged in the discovery and development of breakthrough medicines to treat oncology, central nervous system (CNS) and autoimmune diseases. Website
1) F.D.A. Approves Addyi, a Libido Pill for Women – New York Times, 8/18/2015
The first prescription drug to enhance women’s sexual drive won regulatory approval on Tuesday, clinching a victory for a lobbying campaign that had accused the Food and Drug Administration of gender bias for ignoring the sexual needs of women.
2) Baxalta’s Cambridge-based R&D chief describes new model as ‘small R, big D’ – BBJ, 8/20/2015
Since Baxalta rejected a $30 billion bid from Shire last month, Baxalta CEO Ludwig Hantson has called the company’s pipeline of potential drugs “underappreciated” and said that “the new research and development model is gaining positive momentum.”
3) Sarepta and BioMarin race for an FDA tag that could be worth $350M-plus – FierceBiotech, 8/21/2015
Rivals Sarepta Therapeutics ($SRPT) and BioMarin Pharmaceutical ($BMRN) are in line to become the next recipients of an FDA coupon for a fast review, each potentially picking up a sellable asset that recently brought in $350 million on the open market.
4) GlaxoSmithKline flips an MS project to Novartis for up to $1B – FierceBiotech, 8/21/2015
Novartis ($NVS) is paying GlaxoSmithKline ($GSK) as much as $1 billion for the rights to a mid-stage multiple sclerosis treatment, betting it can develop an heir to the blockbuster Gilenya, soon to lose patent protection.
5) Biogen teams up with Columbia to decode ALS – FierceBiotech, 8/18/2015
Biogen ($BIIB) is joining Columbia University in an effort to sequence the genes of 1,500 people with amyotrophic lateral sclerosis, or ALS, hoping to better understand the disease’s underlying biology to inform drug R&D.
Congress had a busy July before heading home for the August summer recess. The legislative agenda was dominated by debate over the expiring Highway Bill, with lawmakers temporarily extending the highway program until the end of October. Government funding for Fiscal Year 2016 (FY16) was thrown into doubt as the appropriations process stalled due to multiple controversies. Discussions over tax and health issues advanced while the President’s plan to curb carbon emissions was met with fierce GOP resistance. Defense and foreign policy issues came to the fore in July, and legislators continued to look for a path forward on a host of other issues, including cybersecurity, patent reform, and the expired Export-Import Bank.
When Congress reconvenes after Labor Day, lawmakers will have approximately a dozen legislative days to deal with a host of deadline driven items. Most notably, Congress will have to quickly find a path forward on federal funding or risk another government shutdown at the end of September.
Debate over the Highway Bill and funding for the Highway Trust Fund (HTF) reached its peak in July as Congress passed a temporary extension of the Highway Bill, just before the July 31 deadline.
Throughout July, lawmakers struggled to reach a compromise on what to do with the Highway Bill, which was set to expire on July 31, and the Highway Trust Fund (HTF), which was predicted to require an injection of funds by early August.
In the Senate, Environment and Public Works (EPW) Committee Chairman Jim Inhofe (R-OK) and Ranking Member Barbara Boxer (D-CA) continued to push for their “Developing Reliable and Innovative Vision for the Economy” (DRIVE) Act. The bill would fund surface transportation programs at a level of $275 billion over six years, which is a three percent increase in overall annual spending compared to current levels. The DRIVE Act picked up a powerful ally in Senate Majority Leader Mitch McConnell (R-KY). Despite opposition to several of the bill’s provisions, including a reauthorization of the expired Export-Import Bank (see Other Issues section), the Senate approved the measure on a bipartisan 65-34 vote. Leader McConnell’s efforts to bring together Senator Boxer and a large number of her Democratic colleagues allowed the Senate to pass the first Highway Bill that extends funding beyond a two year period since SAFETEA-LU (the last long-term Highway Bill) expired in September 2009. Read the rest of this entry